Neupogen filgrastim: Marketed

Results from five separate Phase III trials involving a total of 1,707 patients that examined survival of breast cancer patients when treated with either high dose chemotherapy plus bone marrow or stem cell transplants or treated with standard chemotherapy alone did not yield definitive conclusions about the two procedures. In four of the trials, there was no statistically significant difference in survival, while in the fifth trial there was a significant benefit of the high dose chemotherapy approach. The data will be presented at the American Society of Clinical Oncology meeting in May in Atlanta.

Separate Phase III trials of the high dose approach in breast cancer patients are ongoing. The National Cancer Institute noted that high dose chemotherapy plus bone marrow transplant is the most effective therapy for other types of cancer such as certain types of leukemia and lymphoma. ...